StockData
GT Biopharma, Inc. logo

GT Biopharma, Inc. (GTBP) stock

GTBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 5/30
$3.18−0.35 (-10.04%)

Close on Nov 17, 2026Market cap $143.45MP/E –Yield –

GT Biopharma total assets

Total assets on the balance sheet at the end of each period.

GT Biopharma's total assets was $8.11M at Dec 31, 2025. For fiscal 2025 it was $8.11M, up 91.5% from the year before. Over ten years it grew 65.1% a year on average. The highest annual figure on record is $254.37M in fiscal 2017.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$8.11M+91.5%
FY2024Dec 31, 2024$4.23M-70.0%
FY2023Dec 31, 2023$14.11M-15.7%
FY2022Dec 31, 2022$16.74M-48.0%
FY2021Dec 31, 2021$32.17M+468.3%
FY2020Dec 31, 2020$5.66M+1329.5%
FY2019Dec 31, 2019$396.00K-98.4%
FY2018Dec 31, 2018$25.40M-90.0%
FY2017Dec 31, 2017$254.37M+1017372.0%
FY2016Dec 31, 2016$25.00K-53.7%
FY2015Dec 31, 2015$54.00K-93.9%
FY2014Dec 31, 2014$888.00K+504.1%
FY2013Dec 31, 2013$147.00K-35.0%
FY2012Dec 31, 2012$226.00K+75.2%
FY2011Dec 31, 2011$129.00K-30.3%
FY2010Dec 31, 2010$185.00K–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025$8.11M+19.9%
Q3 FY2025Sep 30, 2025$4.32M-53.4%
Q2 FY2025Jun 30, 2025$7.12M-28.1%
Q4 FY2024Dec 31, 2024$4.23M-70.0%
Q3 FY2024Sep 30, 2024$6.76M-58.1%
Q2 FY2024Jun 30, 2024$9.27M-48.9%
Q1 FY2024Mar 31, 2024$9.91M-50.7%
Q4 FY2023Dec 31, 2023$14.11M-15.7%
Q3 FY2023Sep 30, 2023$16.15M-23.4%
Q2 FY2023Jun 30, 2023$18.14M-24.9%
Q1 FY2023Mar 31, 2023$20.09M-26.8%
Q4 FY2022Dec 31, 2022$16.74M-48.0%
Q3 FY2022Sep 30, 2022$21.07M+272.2%
Q2 FY2022Jun 30, 2022$24.17M+2535.8%
Q1 FY2022Mar 31, 2022$27.44M+2481.3%
Q4 FY2021Dec 31, 2021$32.17M+10804.7%
Q4 FY2020Dec 31, 2020$5.66M+1329.5%
Q3 FY2020Sep 30, 2020$917.00K+90.2%
Q2 FY2020Jun 30, 2020$1.06M-95.9%
Q1 FY2020Mar 31, 2020$295.00K-98.8%
Q4 FY2019Dec 31, 2019$396.00K-98.4%
Q3 FY2019Sep 30, 2019$482.00K-98.2%
Q2 FY2019Jun 30, 2019$25.71M-89.9%
Q1 FY2019Mar 31, 2019$25.54M-90.1%
Q4 FY2018Dec 31, 2018$25.40M-90.0%
Q3 FY2018Sep 30, 2018$26.54M-89.7%
Q2 FY2018Jun 30, 2018$255.01M+607076.2%
Q1 FY2018Mar 31, 2018$257.33M+108023.1%
Q4 FY2017Dec 31, 2017$254.37M+1017372.0%
Q3 FY2017Sep 30, 2017$256.52M+160225.0%
Q2 FY2017Jun 30, 2017$42.00K–
Q1 FY2017Mar 31, 2017$238.00K–
Q4 FY2016Dec 31, 2016$25.00K–
Q3 FY2016Sep 30, 2016$160.00K–

More GT Biopharma figures

See a number that looks wrong?